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e present special issue provides a synthesis of currentmate-
rials and techniques used to not only explore, but also to vali-
date and evaluate novel markers, potentially new biomarkers,
in the �eld of dementias associated with Alzheimer’s and
Lewy body pathology. is topic is of particular interest as
only a veryminor proportion of potentialmarkers detected in
preclinical studieswill ultimately be included in larger clinical
studies or for routine clinical use.
e review article by Wang et al. focuses on an exciting
and novel topic in the �eld, the potential of the quanti�cation
of small brain protein degradation fragments in blood,
which are generated speci�cally by brain-derived proteases,
to diagnose and follow neurodegenerative processes. e
authors thoroughly review the currently available literature.
ey then speculate on the utility of this strategy as a method
of choice for the development of novel biomarkers for disease
progression, stage of disease, and treatment eﬃcacy in large
cohorts of demented patients as well as individuals at risk
for neurodegenerative dementias. A speci�c focus is on
the potential of tau-, APP-, and alpha-synuclein-associated
fragments.
e review of Deleidi and Maetzler argues that distur-
bances in protein clearance mechanisms in the brain sub-
stantially contribute to neurodegenerative dementias asso-
ciated with Abeta and Lewy body pathology. In fact, much
evidence has been accumulated pointing to defective protein
clearance mechanisms involved in the initiation and progress
of sporadic Alzheimer’s disease. e authors provide, for the
�rst time, an extensive overview of the literature dealing with
protein clearance aspects in the �eld of Lewy body-associated
dementias, with a particular focus on intraneuronal and
extraneuronal clearance mechanisms of Abeta and alpha-
synuclein.
Alpha-synuclein, and the detection of its monomeric
and oligomeric species in cerebrospinal �uid and blood of
patients with dementia with Lewy bodies, is also the central
focus of the review provided by Kasuga et al. e authors
conclude that the determination of altered alpha-synuclein
species such as truncated, phosphorylated, and oligomeric
forms in body �uids may have a far higher potential to
diﬀerentiate between healthy and disease state compared to
the measurement of unaltered alpha-synuclein levels.
In addition to the review papers, there are several
research papers included in this special issue highlighting
new research in the �eld. �aldin et al. assess the associations
between neuropsychological outcomes and pro- and anti-
in�ammatory serum markers in a large cohort of patients
with Alzheimer’s disease and controls. eir results suggest
that individuals with cognitive impairment possess diﬀerent
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proin�ammatory and anti-in�ammatory �strategies� com-
pared to those without. e authors argue that combinations
of in�ammation and neuropsychological measures, as pre-
sented in their study, may improve diagnostic quality. As this
is a baseline assessment of a longitudinal study, we expect that
the initial results concerning the predictive diagnostic value
of this approach—which are even more interesting—will
soon be available. is article �ts well in a rapidly growing
number of important articles reporting about the usefulness
of combinations of outcome measures to de�ne state, trait,
and risk of chronic (neurodegenerative) diseases.
Schreitmüller et al. assess vascular markers by
Alzheimer’s disease severity. eir research is based on
the idea that in Alzheimer’s disease a continuous vascular
activation, induced by hypoperfusion and factors and
processes associated with angiogenesis, occurs. In their study,
the authors investigated serum levels of the proangiogenic
factor Angiopoietin-1 in patients with Alzheimer’s disease,
mild cognitive impairment, and controls. ey found higher
levels in patients with Alzheimer’s disease and concluded
that Angiopoietin-1 is a potential candidate for a respective
biomarker panel.
Duchesne et al. provide another (if not the most impor-
tant) piece in the biomarkers’ development puzzle. ey
nicely illustrate the importance of implementing adequate
veri�cation, validation, and evaluation steps before a promis-
ing marker can be integrated into large scale studies or
even routine clinical assessment. More speci�cally, they
report both thewithin-session scan/repeat and across-session
scan/rescan reliability (a component of validity) of a self-
developed assessment tool that detects medial temporal lobe
atrophy via MRI images. In their article, they end up with
a power calculation, that is, an estimation of minimum
precision threshold that must be added to the eﬀect size, to
obtain true cohort sizes for clinical trials.
Lastly, Liepelt-Scarfone et al. report on the diagnostic
utility of neuropsychological test results obtained from a
large cohort of nondemented and demented patients with
Parkinson’s disease. In this paper, the authors introduce fac-
tor and cluster analysis strategies that enable a diﬀerentiation
between diﬀerent subtypes of Parkinson’s disease patients, a
detection of similarities between test results, and a reduction
of a large number of markers on an explorative, hypothesis-
free basis. ese are particularly important approaches to
increase the quality of clinical data that are included in
biomarker studies, and to improve our understanding about
pheno- and endophenotypes in respective disorders.
It must be emphasized that the evaluation of any therapy
is heavily depending on the existence of suﬃcient trait and
state markers which are currently, in particular in Lewy body
disorders, not available. With this respect, we feel that this
special issue oﬀers both review articles and original research
which provide a comprehensive overview of promising (com-
binations of) biomarkers aswell as state-of-the-art techniques
to evaluate them. We hope this issue will stimulate the
continuing eﬀorts towards developing promising and reliable
markers for these particularly burdensome disorders.
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